Protease inhibitor-sparing regimens.
Smith
Kimberly Y
KY
Department of Medicine, Rush Medical College, Rush-Presbyterian-St. Luke's Medical Center, Chicago, USA. ksmith2@rush.edu
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D010349:Patient Compliance; D019562:Viral Load; D015215:Zidovudine / Q000627:therapeutic use
D019380:Anti-HIV Agents; D004338:Drug Combinations; D017320:HIV Protease Inhibitors; C109078:lamivudine, zidovudine drug combination; D019259:Lamivudine; D015215:Zidovudine